The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Tesofensine

TRI

C
Animal replicated
Research chemicalTriple Monoamine Reuptake InhibitorSmall MoleculeAnti-Obesity Drug
RouteOralGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
NS2330 — Triple Monoamine Reuptake Inhibitor (TRI) — Oral Small Molecule Weight Loss Agent — Triple Monoamine Reuptake Inhibitor, Small Molecule, Anti-Obesity Drug.
Why people use it
Used primarily for weight loss and cognitive support.
What the evidence supports
ABSOLUTE DRUG INTERACTION CONTRAINDICATIONS — READ BEFORE ANY OTHER SECTION
If you only read one thing

Tesofensine has the most impressive weight loss efficacy data of any mechanistically novel oral weight loss compound not yet approved by the FDA or EMA. The Lancet 2008 Phase 2b data (10.6% net body weight loss at 0.5mg over 24 weeks) exceeds most approved anti-obesity medications of its era and rivals GLP-1 agents in some head-to-head comparisons. It works through a completely different mechanism from GLP-1 — directly targeting dopamine, norepinephrine, and serotonin reuptake in the brain rather than gut hormones and satiety signaling — offering potential for patients who do not respond to GLP-1 or who prefer an oral mechanism. The cardiovascular liability (7-8 bpm heart rate increase, 1-3 mmHg blood pressure increase) is the sole obstacle between tesofensine and regulatory approval. Saniona's Tesomet combination with metoprolol addresses this pharmacologically; Phase 3 will determine if the market strategy succeeds. Community users are self-administering tesofensine without the metoprolol component that was deemed necessary for regulatory approval — and without cardiovascular monitoring.

Check interactions →
Published literature
2human RCTs0human studies2animal1in vitro

Human controlled evidence includes the published oral obesity Phase 2b trial and earlier neurodegenerative Phase 2 programs; no Phase 3 cardiovascular-outcomes or approval-level obesity data exist.

Evidence reality check
Human evidence
2 human studies
2 randomized; 0 observational.
Preclinical base
3 lab signals
2 animal; 1 in-vitro/mechanistic.
Evidence snapshot
ABSOLUTE DRUG INTERACTION CONTRAINDICATIONS — READ BEFORE ANY OTHER SECTION
From the chapter quick-reference block.
Categories
Weight Loss & MetabolicCognition & Mood
Properties
✓ Human RCTNot injectable
Evidence
CAnimal replicated
The Accidental Weight Loss Discovery
Tesofensine was originally developed by NeuroSearch for neurodegenerative disorders — Alzheimer's disease and Parkinson's disease. Phase 2 trials for these indications failed to demonstrate efficacy. However, significant weight loss was observed as a side effect in Parkinson's disease trial participants. NeuroSearch pivoted the development program entirely to obesity. This origin story is relevant context: tesofensine was not designed as an obesity drug — its pharmacological profile was not optimized for weight loss, which may partly explain both its impressive efficacy and its cardiovascular side effect profile.
The Lancet 2008 Phase 2b Data
Astrup et al. (2008, Lancet): n=203 obese adults; 24 weeks; randomized double-blind placebo-controlled. Doses: 0.25mg, 0.5mg, 1.0mg/day vs placebo (all with mild caloric restriction). Mean weight loss: 0.25mg = 6.7%; 0.5mg = 11.3%; 1.0mg = 12.8%. Net weight loss (vs placebo at 2.0%): 0.5mg = 9.2%; 1.0mg = 10.6%. This was approximately double what sibutramine produced at the time and exceeds most anti-obesity drugs of that era. Improvements in waist circumference, lipids, glucose. The 0.5mg dose became the development focus — effective and somewhat better tolerated than 1.0mg.
The Heart Rate Problem — Why It's Not Approved
At 0.5mg: heart rate increased +6.7 bpm vs placebo. At 1.0mg: +7.7 bpm. 56.2% of 1.0mg subjects had ≥10 bpm HR increase on ECG vs 18.8% of placebo. Blood pressure: 1-3 mmHg increase at therapeutic doses. This cardiovascular signal mirrors sibutramine — a dual NET/SERT inhibitor withdrawn worldwide in 2010 after the SCOUT trial showed increased major cardiovascular events (MI, stroke) in high-risk patients. Post-sibutramine, regulators require cardiovascular outcome trials (CVOTs) for obesity drugs — expensive, multi-year programs that NeuroSearch could not fund before going bankrupt.
Tesomet — The Heart Rate Solution
Saniona A/S (which acquired tesofensine from NeuroSearch) recognized that tesofensine would not receive approval as a standalone compound. Their solution: combine tesofensine 0.5mg with metoprolol 25-50mg in a fixed-dose combination product (Tesomet). Metoprolol is a β1-selective adrenoceptor blocker that specifically counteracts the heart rate and blood pressure elevation from tesofensine's NET inhibition while preserving the weight loss efficacy. Phase 1 drug interaction studies and Phase 2 in T2D patients showed: Tesomet combination eliminated the HR increase while maintaining weight loss. COFEPRIS (Mexico) approved Tesomet (brand: Nupenta) in 2023 — the only regulatory approval to date. Tesomet Phase 3 is ongoing as of 2026.
Community Status and Drug Interactions
Tesofensine is available as a research chemical from various vendors (typically 0.5mg capsules). It is NOT a compounded medication under physician supervision in the same way as, for example, BPC-157 from US 503B pharmacies. Community use is without medical oversight or quality assurance of pharmaceutical grade. ABSOLUTE DRUG INTERACTION CONTRAINDICATIONS: SSRIs, SNRIs — additive serotonin reuptake inhibition → serotonin syndrome risk. All MAO inhibitors — MAOI + TRI = extremely high serotonin syndrome risk. Other stimulants — additive cardiovascular and CNS stimulant effects. WADA: not currently prohibited but stimulant-class compound; monitor for future listing.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
5-Amino-1MQ
C
Same class · Small Molecule

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

ATX-304
C
Same class · Small Molecule

Oral small-molecule pan-AMPK activator and mitochondrial uncoupler in active Phase 1b/2 clinical development. Formerly O-304, now ATX-304 under Amplifier Therapeutics / Cambrian Bio. Phase 2a human data show fasting glucose reduction in type 2 diabetes; obesity and cardiometabolic outcomes remain investigational.

BAM15
C
Same class · Small Molecule

The Mitochondrial Uncoupler That Doesn't Kill You. DNP Kills People in 2026. BAM15 Was Designed to Solve That. Fat Loss Without Hyperthermia. Without Reduced Food Intake. Without Lean Mass Loss. Without Toxicity Markers. In Mice. Nature Communications 2020. Zero Human Trials. The Most Mechanistically Elegant Fat Loss Compound in this reference — and the Most Preclinical.

Check interactions